Search Results

You are looking at 1 - 3 of 3 items for

  • Author or Editor: Michelle Lim x
  • Refine by Content Type: All x
Clear All Modify Search
Michelle G.A. Lim and Edgar V. Lerma

Sodium glucose cotransporter-2 (SGLT2) inhibitors currently approved by the US Food and Drug Administration include empagliflozin (Jardiance), canagliflozin (Invokana), dapagliflozin (Farxiga), and ertugliflozin (Steglatro). Combination formulations are also available: empagliflozin/metformin (Synjardy), canagliflozin/metformin (Invokamet), dapagliflozin/metformin (Xigduo XR), and ertugliflozin/metformin (Segluromet).

For this year’s Kidney Watch, we look once again at the diabetic kidney disease (DKD) space as these agents enter the world of nephrology (1).

On September 30, 2020, the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2) was published. There continues to be increased discussion surrounding the

Edgar V. Lerma and Michelle G.A. Lim

Diabetic kidney disease (DKD) has been in the forefront of industry publications during these challenging yet exciting times. With the advent of recognition of sodium glucose co-transporter 2 (SGLT2) inhibitors and their particular outcome benefits in patients with type 2 diabetes who are particularly prone to developing complications related to cardiovascular (CV) disease, there has been revitalization of our understanding of the mineralocorticoid receptor and the central role it plays in inflammation and fibrosis involving the kidneys.

A nonsteroidal mineralocorticoid antagonist—finerenone—was highlighted in several major randomized controlled trials (1, 2) that enrolled adult patients with chronic

Isabelle Dominique Tomacruz, Corina Teodosiu, Sophia L. Ambruso, and Michelle Lim
The rise of social media (SoMe) and free open-access medical education (#FOAMed)

The internet and social media have revolutionized the way medical information is disseminated, presented, and consumed. There is a rapid uptake of virtual and mobile-optimized modalities, where FOAMed tools are becoming a preferred modality for medical education (15). FOAMed differs from traditional medical education in that teaching and learning occur asynchronously within the virtual space, outside of traditional institutions and a lecture-based format. Although virtual education has grown exponentially over the last several decades, gaining the skills to harness social media as an educational